Τίτλος:
Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: A pooled analysis
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ≥ 484 and <1,000] or (ii) high seroreactivity (MFI ≥1,000). Associations of moderate and high HPV16 E6 seroreactivity with (i) demographic risk factors; and seropositivity for (ii) other HPV16 proteins (E1, E2, E4, E7, and L1), and (iii) E6 proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45, and 52) were evaluated. Results: Thirty-two (0.7%)HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2-51.8], and seropositivity againstHPV16 L1 (OR, 4.8; 95% CI, 1.3-15.4); E2 (OR, 7.7; 95% CI, 1.4-29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6-119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9-81.8). No associations were observedwithmoderateHPV16 E6 seroreactivity. Conclusions: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. Impact: Some HPV16 E6 seropositive individuals without diagnosedHPV-drivencancer,especiallythosewithseropositivityagainst other HPV16 proteins, may harbor a biologically relevant HPV16 infection. Cancer Epidemiol Biomarkers Prev; 24(4); 683-9. © 2015 AACR.
Συγγραφείς:
Lang Kuhs, K.A.
Anantharaman, D.
Waterboer, T.
Johansson, M.
Brennan, P.
Michel, A.
Willhauck-Fleckenstein, M.
Purdue, M.P.
Holcátová, I.
Ahrens, W.
Lagiou, P.
Polesel, J.
Simonato, L.
Merletti, F.
Healy, C.M.
Kjaerheim, K.
Conway, D.I.
Macfarlane, T.V.
Thomson, P.
Castellsagué, X.
Znaor, A.
Black, A.
Huang, W.-Y.
Krogh, V.
Trichopoulou, A.
Bueno-De-Mesquita, H.B.A.S.
Clavel-Chapelon, F.
Weiderpass, E.
Ekström, J.
Riboli, E.
Tjønneland, A.
Sánchez, M.-J.
Travis, R.C.
Hildesheim, A.
Pawlita, M.
Kreimer, A.R.
Περιοδικό:
Cancer Epidemiology Biomarkers and Prevention
Εκδότης:
American Association for Cancer Research Inc.
Λέξεις-κλειδιά:
glycoprotein E1; Human papillomavirus type 16 E6 antibody; protein E6; protein E7; unclassified drug; virus antibody; E6 protein, Human papillomavirus type 16; oncoprotein; repressor protein; virus antibody, adult; aged; Article; controlled study; demography; female; human; Human papillomavirus type 11; Human papillomavirus type 16; Human papillomavirus type 18; Human papillomavirus type 31; Human papillomavirus type 33; Human papillomavirus type 45; Human papillomavirus type 52; Human papillomavirus type 6; major clinical study; male; neoplasm; nonhuman; priority journal; risk factor; blood; case control study; cohort analysis; enzyme linked immunosorbent assay; immunology; middle aged; oropharynx tumor; papillomavirus infection; squamous cell carcinoma; very elderly; virology; young adult, Adult; Aged; Aged, 80 and over; Antibodies, Viral; Carcinoma, Squamous Cell; Case-Control Studies; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Female; Human papillomavirus 16; Humans; Male; Middle Aged; Oncogene Proteins, Viral; Oropharyngeal Neoplasms; Papillomavirus Infections; Repressor Proteins; Risk Factors; Young Adult
DOI:
10.1158/1055-9965.EPI-14-1217
